Table 2 Effect of weight loss in non‐alcoholic fatty liver disease in adults.

Author	Intervention	Number	Study Type	Comparison	Duration (months)	ALT	Histology
							Steatosis	Inflammation	Fibrosis
Ueno32	Diet/exercise	25	Open label, non‐randomised	No treatment	3	Improved	Improved	No change	No change
Huang29	Diet/exercise	23	Pilot trial	Baseline	12	No change	No change	No change	No change
Andersen28	Diet	41	Case series	Baseline	6	Improved	Improved	No change*	No change
Okita30	Diet	14	Pilot trial	Baseline	6	Improved	NA	NA	NA
Palmer31	Diet	39	Case series	Baseline		Improved	NA	NA	NA
Harrison38	Orlistat	10	Pilot trial	Baseline	6	Improved	No change	No change	No change
HatzitoliosA35	Orlistat	21	Pilot trial	Baseline	6	Improved	NA	NA	NA
Sabuncu40	Orlistat	12	Pilot trial	Baseline	6	Improved	Improved†	NA	NA
	Sibutramine	13	Pilot trial	Baseline	6	Improved	Improved†	NA	NA
Dixon41	Gastric banding	36	Pilot trial	Baseline	26	Improved	Improved	Improved	Improved
Silverman44	Gastro‐jejenostomy	91	Case series	Baseline	18	No change	Improved	No change	Improved
Luyckx43	Gastric banding	69	Case series	Baseline	27	Improved	Improved	Worse	No change
Kral42	Biliopancreatic diversion	104	Case series	Baseline	74	Improved	Improved	No change	Worse‡
Clark JM92	Reux‐en Y gastric bypass	16	Case series	Baseline	10	No change	Improved	Improved	Improved

NA, not assessed. *No change in lobular inflammation, but significant worsening of portal inflammation; †as assessed by ultrasound; ‡significance level p = 0.053.